Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center

BACKGROUND: Large randomized clinical trials of patients with type 2 diabetes mellitus (T2DM) and at high risk for cardiovascular disease revealed that sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduced renal events. However, the trials included small numbers of patients with mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugiyama, Seigo, Jinnouchi, Hideaki, Yoshida, Akira, Hieshima, Kunio, Kurinami, Noboru, Jinnouchi, Katsunori, Tanaka, Motoko, Suzuki, Tomoko, Miyamoto, Fumio, Kajiwara, Keizo, Jinnouchi, Tomio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436561/
https://www.ncbi.nlm.nih.gov/pubmed/30937117
http://dx.doi.org/10.14740/jocmr3761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436561/
https://www.ncbi.nlm.nih.gov/pubmed/30937117
http://dx.doi.org/10.14740/jocmr3761

Ejemplares similares